Biofabri

Executive Summary

Biofabri, a Spanish biotechnology company and member of the Zendal Group, is dedicated to developing novel vaccines and immunotherapies for human health. Founded in 2008 and headquartered in Porriño, Spain, the company's lead program is MTBVAC, a live-attenuated vaccine candidate for tuberculosis (TB). TB remains a major global health threat, and the only licensed vaccine, BCG, offers limited efficacy in adults. MTBVAC aims to provide superior protection across all age groups and has shown promising preclinical results. Biofabri's focus on innovative biologics positions it as a key player in the fight against infectious diseases, with potential applications beyond TB. Despite being in the preclinical stage, Biofabri has attracted attention for its MTBVAC platform, which is based on a genetically modified version of the TB pathogen. The company is now poised to advance its pipeline toward clinical development. Upcoming catalysts include the initiation of first-in-human trials, potential strategic partnerships with global health organizations or pharmaceutical companies, and the release of key preclinical data. Success in these milestones could validate the technology and unlock significant value, positioning Biofabri for growth in the competitive vaccine landscape.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 Clinical Trial for MTBVAC60% success
• TBDPartnership or Licensing Agreement for MTBVAC40% success
• TBDPublication of Key Preclinical Data in Peer-Reviewed Journal70% success